TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE SYSTEM
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 RISE IN THE NUMBER OF STRATEGIC INITIATIVES
4.2.2 BENEFITS ASSOCIATED WITH PHARMACY MANAGEMENT SYSTEMS
4.2.3 BURDEN ON PHARMACISTS DUE TO INCREASING NUMBER OF PRESCRIPTIONS
4.3 RESTRAINTS
4.3.1 COMPLEX FEATURES SUCH AS VENDOR LOCK-IN
4.4 OPPORTUNITIES
4.4.1 INCREASING DEMAND FOR PHARMACY MANAGEMENT SYSTEMS IN EMERGING ECONOMIES
4.5 CHALLENGES
4.5.1 UNAVAILABILITY OF TRAINED PROFESSIONALS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 INPUTS
5.1.2 SOFTWARE DEVELOPMENT PROCESSES
5.1.3 OUTPUT
5.1.4 MARKETING AND DISTRIBUTION
5.1.5 POST-SELLING SERVICES
5.1.5.1 SOFTWARE MAINTENANCE SERVICES & AGREEMENTS
5.1.5.2 TRAINING & CERTIFICATIONS
5.1.5.3 SUPPORT: TECHNICAL & GRIEVANCE AID
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE PHARMACY MANAGEMENT SYSTEM MARKET
6 GLOBAL PHARMACY MANAGEMENT SYSTEM MARKET, BY SOLUTION TYPE
6.1 OVERVIEW
6.2 PHARMACY INVENTORY MANAGEMENT SYSTEM
6.3 PHARMACY DATA MANAGEMENT SYSTEM
6.4 PHARMACY COMPOUNDING SOFTWARE SYSTEM
6.5 PHARMACY BENEFITS MANAGEMENT SYSTEM
6.6 PHARMACY REVENUE CYCLE MANAGEMENT SYSTEM
6.7 OTHERS
7 GLOBAL PHARMACY MANAGEMENT SYSTEM MARKET, BY COMPONENT
7.1 OVERVIEW
7.2 SOFTWARE
7.3 HARDWARE
7.4 SERVICES
8 GLOBAL PHARMACY MANAGEMENT SYSTEM MARKET, BY DEPLOYMENT MODE
8.1 OVERVIEW
8.2 CLOUD/WEB-BASED
8.3 ON-PREMISE
9 GLOBAL PHARMACY MANAGEMENT SYSTEM MARKET, BY END USER
9.1 OVERVIEW
9.2 INPATIENT PHARMACIES
9.3 OUTPATIENT PHARMACIES
10 PHARMACY MANAGEMENT SYSTEMS, BY REGION
10.1 OVERVIEW
10.2 AMERICAS
10.2.1 NORTH AMERICA
10.2.1.1 US
10.2.1.2 CANADA
10.3 EUROPE
10.3.1 WESTERN EUROPE
10.3.1.1 GERMANY
10.3.1.2 FRANCE
10.3.1.3 UK
10.3.1.4 ITALY
10.3.1.5 SPAIN
10.3.1.6 NETHERLANDS
10.3.1.7 SWITZERLAND
10.3.1.8 BELGIUM
10.3.1.9 AUSTRIA
10.3.1.10 REST OF WESTERN EUROPE
10.3.2 EASTERN EUROPE
10.4 ASIA-PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 AUSTRALIA
10.4.5 SOUTH KOREA
10.4.6 TAIWAN
10.4.7 NEW ZEALAND
10.4.8 THAILAND
10.4.9 PHILIPPINES
10.4.10 REST OF ASIA-PACIFIC
10.5 MIDDLE EAST & AFRICA
10.5.1 MIDDLE EAST
10.5.2 AFRICA
11 COMPETITIVE LANDSCAPE
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
11.6.2 MERGER & ACQUISITIONS
11.6.3 AGREEMENT/MARKETING STRATEGIES
12 COMPANY PROFILES
12.1 ALLSCRIPTS HEALTHCARE, LLC
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 CERNER CORPORATION
12.2.1 COMPANY OVERVIEW
12.2.2 PRODUCTS OFFERED
12.2.3 PRODUCTS OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 DATASCAN PHARMACY
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 KEY STRATEGIES
12.4 EPICOR SOFTWARE CORPORATION
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 GLOBEMED GROUP
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 LIBERTY SOFTWARE, INC.
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIES
12.7 LS RETAIL EHF
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 KEY STRATEGIES
12.8 MCKESSON CORPORATION
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 MEDHOK, INC.
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIES
12.10 OCTAL IT SOLUTION LLP
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
12.11 SAFECARE TECHNOLOGY
12.11.1 COMPANY OVERVIEW
12.11.2 FINANCIAL OVERVIEW
12.11.3 PRODUCTS OFFERED
12.11.4 KEY DEVELOPMENTS
12.11.5 KEY STRATEGIES
12.12 SCRIPTPRO LLC
12.12.1 COMPANY OVERVIEW
12.12.2 FINANCIAL OVERVIEW
12.12.3 PRODUCTS OFFERED
12.12.4 KEY DEVELOPMENTS
12.12.5 KEY STRATEGIES
12.13 CLANWILLIAM HEALTH
12.13.1 COMPANY OVERVIEW
12.13.2 FINANCIAL OVERVIEW
12.13.3 PRODUCTS OFFERED
12.13.4 KEY DEVELOPMENTS
12.13.5 KEY STRATEGIES
12.14 MOBILE MEDSOFT
12.14.1 COMPANY OVERVIEW
12.14.2 FINANCIAL OVERVIEW
12.14.3 PRODUCTS OFFERED
12.14.4 KEY DEVELOPMENTS
12.14.5 KEY STRATEGIES
12.15 HEALTH BUSINESS SYSTEMS, INC.
12.15.1 COMPANY OVERVIEW
12.15.2 FINANCIAL OVERVIEW
12.15.3 PRODUCTS OFFERED
12.15.4 KEY DEVELOPMENTS
12.15.5 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
